Latest news

• Eli Lilly focuses on 2022 launches as revenues climb by 18%

  The second is a new drug application (NDA) to the FDA and a marketing authorisation application to the European Medicines Agency (EMA) for tirzepatide for the treatment of adults with type ... through 2030, bolstered by multiple pipeline readouts of its

• Lilly showcases tirzepatide type 2 diabetes data at ADA 2021

  Company is planning to submit the full data package for tirzepatide to regulatory authorities by the end of 2021. ... Tirzepatide is an investigational once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist.

• Novo Nordisk reveals positive results at ADA 2021 for higher-dose Ozempic in type 2 diabetes

  The company may face new competition in the type 2 diabetes area soon, as a regulatory filing for Eli Lilly’s investigational GIP and GLP-1 receptor agonist tirzepatide looms. ... Also at ADA, Lilly revealed that all doses of tirzepatide tested in a

• Lilly partners with Biolojic Design to develop diabetes antibody therapies

  Among these is tirzepatide, which recently yielded positive results in a head-to-head trial against Novo Nordisk’s semaglutide in type 2 diabetes. ... Tirzepatide demonstrated superiority compared to semaglutide in all doses tested, with the highest

• Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial

  Tirzepatide demonstrated superiority compared to semaglutide in all doses tested, with the highest dose – 15mg – reducing A1C by 2.46% and body weight by 13.1%. ... Tirzepatide is Lilly’s investigational once-weekly dual glucose-dependent